MX387200B - Extracto de streptococcus uberis como agente inmunogénico. - Google Patents

Extracto de streptococcus uberis como agente inmunogénico.

Info

Publication number
MX387200B
MX387200B MX2018009048A MX2018009048A MX387200B MX 387200 B MX387200 B MX 387200B MX 2018009048 A MX2018009048 A MX 2018009048A MX 2018009048 A MX2018009048 A MX 2018009048A MX 387200 B MX387200 B MX 387200B
Authority
MX
Mexico
Prior art keywords
relates
immunogenic agent
biofilm
agent
extract
Prior art date
Application number
MX2018009048A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009048A (es
Inventor
I Amargós Antoni Prenafeta
Gimbert Rosa Maria Collado
Original Assignee
Hipra Scient S L U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hipra Scient S L U filed Critical Hipra Scient S L U
Publication of MX2018009048A publication Critical patent/MX2018009048A/es
Publication of MX387200B publication Critical patent/MX387200B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2018009048A 2016-02-15 2017-02-14 Extracto de streptococcus uberis como agente inmunogénico. MX387200B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382060 2016-02-15
PCT/EP2017/053306 WO2017140683A2 (en) 2016-02-15 2017-02-14 Streptococcus uberis extract as an immunogenic agent

Publications (2)

Publication Number Publication Date
MX2018009048A MX2018009048A (es) 2019-03-28
MX387200B true MX387200B (es) 2025-03-18

Family

ID=55646514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009048A MX387200B (es) 2016-02-15 2017-02-14 Extracto de streptococcus uberis como agente inmunogénico.

Country Status (11)

Country Link
US (1) US10946085B2 (enExample)
EP (1) EP3417049B1 (enExample)
JP (1) JP6839199B2 (enExample)
KR (1) KR102824686B1 (enExample)
AU (1) AU2017220528A1 (enExample)
CA (1) CA3012419A1 (enExample)
ES (1) ES2960326T3 (enExample)
MX (1) MX387200B (enExample)
PL (1) PL3417049T3 (enExample)
WO (1) WO2017140683A2 (enExample)
ZA (1) ZA201805039B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022352157A1 (en) 2021-09-21 2024-05-02 National Agriculture And Food Research Organization Vaccine including nonencapsulated strain as antigen
EP4570265A1 (en) 2023-12-15 2025-06-18 Zaklad Badawczo-Wdrozeniowy Osrodka Salmonella "Immunolab" Sp. z o.o. Vaccine for use in preventing inflammatory conditions in cows

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60243024A (ja) * 1983-12-29 1985-12-03 Kitasato Inst:The ストレプトコツカス・サンギス感染症予防用ワクチン,診断用抗原および抗体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2222701C (en) 1995-06-08 2012-02-07 University Of Saskatchewan Camp factor of streptococcus uberis
DK1332155T3 (da) 2000-06-12 2007-02-26 Univ Saskatchewan Vaccination af malkekvæg med GapC protein mod streptokokinfektion
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
US8273361B2 (en) 2006-09-26 2012-09-25 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
US20110028407A1 (en) * 2007-02-09 2011-02-03 Jutila Mark A Enhancement of innate resistance to infection
GB0818231D0 (en) 2008-10-06 2008-11-12 Univ Nottingham Composition
EP3461496B1 (en) * 2009-06-22 2023-08-23 Wyeth LLC Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
WO2012116447A1 (en) 2011-03-03 2012-09-07 The Governors Of The University Of Alberta Use of bacterial endotoxins and lipoteichoic acids to improve postpartal health and productivity of dairy cows and their newborns
MX2013013182A (es) 2011-05-12 2013-12-09 Intervet Int Bv Tratamiento de la mastitis.
BR112013032675A2 (pt) * 2011-06-19 2017-08-08 Vaxine Pty Ltd composição adjuvante de vacina compreendendo partículas de inulina
WO2015042423A2 (en) 2013-09-19 2015-03-26 Zoetis Llc Vaccine

Also Published As

Publication number Publication date
KR102824686B1 (ko) 2025-06-25
EP3417049A2 (en) 2018-12-26
PL3417049T3 (pl) 2024-02-19
CA3012419A1 (en) 2017-08-24
WO2017140683A2 (en) 2017-08-24
ZA201805039B (en) 2020-05-27
JP6839199B2 (ja) 2021-03-03
ES2960326T3 (es) 2024-03-04
US20190038736A1 (en) 2019-02-07
MX2018009048A (es) 2019-03-28
KR20180108619A (ko) 2018-10-04
JP2019504623A (ja) 2019-02-21
AU2017220528A1 (en) 2018-08-09
EP3417049B1 (en) 2023-08-16
BR112018015255A2 (pt) 2018-12-18
WO2017140683A3 (en) 2017-10-12
US10946085B2 (en) 2021-03-16

Similar Documents

Publication Publication Date Title
BR112018068593A2 (pt) composições tópicas não aquosas que compreendem uma salicilanilida halogenada
EP4477662A3 (en) Nucleic acid molecules and uses thereof
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2017015881A (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201500054A1 (ru) Аттенуированные вакцины против streptococcus suis и способы их получения и применения
PH12016501988A1 (en) Antibacterial compounds
MX381211B (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
BR112016023613A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX378266B (es) Inhibidores de gingipaina de lisina.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
TN2016000435A1 (en) Novel macrocyclic compounds.
BR112016024096A2 (pt) novo bacteriófago e composição compreendendo o mesmo
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
CL2019001649A1 (es) Método para el control de enfermedades bacterianas de plantas utilizando derivados de carboxamida.
MX2022003871A (es) Composiciones inmunogénicas.
PH12019500570A1 (en) Ketone inhibitors of lysine gingipain
MX387200B (es) Extracto de streptococcus uberis como agente inmunogénico.
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112016029619A2 (pt) novas fluoroquinolonas e sesu usos no tratamento de infecções bacterianas
MX394066B (es) Nuevos compuestos
MX387201B (es) Composiciones para el tratamiento contra infecciones.
BR112018012033A2 (pt) composição imunogênica e método para detectar infecção por h. pylori em um sujeito
BR112016009076A2 (pt) Composição, processos para preparar um compósito de fluoreto de cálcio e uma composição imunogênica, e, métodos para tratamento ou prevenção de uma infecção ou uma doença causada por vírus, bactéria ou parasita e para induzir uma resposta imunogênica em um humano